secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001104659-26-018314
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead to acquire Arcellx for $115/share plus $5 CVR; implied equity value $7.8B
--------------------------------------------------------------------------------

- $115 per share cash at closing plus one contingent value right of $5 per share; total implied equity value ~$7.8B.
- CVR pays $5 if cumulative worldwide sales of anito-cel exceed $6B by Dec 31, 2029.
- FDA accepted BLA for anito-cel in relapsed/refractory multiple myeloma; PDUFA date Dec 23, 2026.
- Transaction expected to close Q2 2026; requires majority tender, regulatory approvals, and customary conditions.
- Gilead currently owns ~11.5% of Arcellx; deal builds on existing Kite collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000110465926018314/0001104659-26-018314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000110465926018314/tm267044d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-018314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer